BRIEF—Daiichi Sankyo launches Minnebro in Japan

Daiichi Sankyo today announced the launch in Japan of Minnebro (esaxerenone) tablets 1.25mg, 2.5mg and 5mg.

The drug is a novel, non-steroidal, selective mineralocorticoid receptor blocker identified during the research collaboration with US drugmaker Exelixis, and has subsequently been developed by Daiichi Sankyo independently.

Marketing approval for the indication of hypertension was received in January, 2019, on the basis of the results of a domestic Phase III clinical trial (ESAX-HTN study) in patients with essential hypertension.

Daiichi Sankyo expects the drug to benefit patients by providing a new therapeutic option for the treatment of hypertension.